An Evaluation of the Effect of Naringenin on Perphenazine-Induced Catatonia in Rats
Abstract
Background and Aim: Parkinson is known as the second most common disease of the nervous system after Alzheimer's disease. Parkinsonism is primarily caused by idiopathic Parkinson's disease. The second most common cause of this disorder is the consumption of drugs. Flavonoid compounds are natural polyphenolic compounds found in many plants. Naringenin (4’, 5, 7-trihydroxyflavanone) is a flavonoid found in fruits and vegetables with various protective effects on the nervous system.Materials and Methods: Rats were divided into five groups of eight rats. The intraperitoneal administration of naringenin was conducted at doses of 100, 200, and 400 mg/kg. The animal received perphenazine thirty minutes following the administration of different doses of naringenin, normal saline and bromocriptine. The rats were analyzed using Morpurgo test for scoring their muscle stiffness 20, 40, 60, 90, 120, 180, and 240 minutes after perphenazine injection. Kruskal-Wallis test was performed to check the differences between the groups (multiple comparisons). We used Mann-Whitney U test in order to compare the distinction between two independent groups.Results: The reduction of the muscle stiffness of the naringenin-intake group was not significant with the dose of 100 mg/kg compared with the positive control group. (P < 0.05). The reductions in stiffness in naringenin intake with the doses of 200 and 400 mg/kg were not remarkable in comparison with the positive control group.Conclusion: According to the results, naringenin does not have any significant effect on catatonia induced by perphenazine in the dose of 100 mg/kg but its infusion in the doses of 200 and 400 mg/kg showed significant reduction in muscle stiffness.References
Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nature Reviews Neuroscience. 2002;3(12):932.
López-Sendón J, Mena MA, G de Yébenes J. Drug-induced parkinsonism. Expert opinion on drug safety. 2013;12(4):487-96.
Mena MA, de Yébenes JG. Drug-induced parkinsonism. Expert opinion on drug safety. 2006;5(6):759-71.
López-Sendón JL, Mena MA, de Yébenes JG. Drug-induced parkinsonism in the elderly. Drugs & aging. 2012;29(2):105-18.
Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. American Journal of Psychiatry. 2003;160(7):1233-41.
Morpurgo C. Effects of antiparkinson drugs on a phenothiazine-induced catatonic reaction. Archives internationales de pharmacodynamie et de thérapie. 1962;137:84-90.
Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, et al. Missing pieces in the Parkinson's disease puzzle. Nature medicine. 2010;16(6):653.
Schwarting R, Huston J. Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions. Neurotoxicology. 1997;18(3):689-708.
Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. neuron. 2003;39(6):889-909.
Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biological Research. 1994;27:105-.
Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. Progress in neurobiology. 1996;48(1):1-19.
Shin H-W, Chung SJ. Drug-induced parkinsonism. Journal of clinical neurology. 2012;8(1):15-21.
Montastruc J, Llau M, Rascol O, Senard J. Drug‐induced parkinsonism: a review. Fundamental & clinical pharmacology. 1994;8(4):293-306.
SHANON J, KAPLAN SM, PIERCE CM, ROSS WD. An interesting reaction to a tranquilizer: tonic seizures with perphenazine (trilafon). American Journal of Psychiatry. 1957;114(6):556-.
Velamoor R. Neuroleptic malignant syndrome: a neuro-psychiatric emergency: recognition, prevention, and management. Asian journal of psychiatry. 2017;29:106-9.
Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annual review of neuroscience. 1990;13(1):171-82.
Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. Journal of pharmacological sciences. 2004;96(3):229-45.
Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free radical biology and medicine. 1996;20(7):933-56.
Schachter SC. Botanicals and herbs: a traditional approach to treating epilepsy. Neurotherapeutics. 2009;6(2):415-20.
Vafeiadou K, Vauzour D, Lee HY, Rodriguez-Mateos A, Williams RJ, Spencer JP. The citrus flavanone naringenin inhibits inflammatory signalling in glial cells and protects against neuroinflammatory injury. Archives of Biochemistry and Biophysics. 2009;484(1):100-9.
Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma OI, Dexter DT. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free radical research. 2005;39(10):1119-25.
Olsen HT, Stafford GI, Van Staden J, Christensen SB, Jäger AK. Isolation of the MAO-inhibitor naringenin from Mentha aquatica L. Journal of Ethnopharmacology. 2008;117(3):500-2.
Shi Y, Dai J, Liu H, Li R-R, Sun P-L, Du Q, et al. Naringenin inhibits allergen-induced airway inflammation and airway responsiveness and inhibits NF-κB activity in a murine model of asthma. Canadian journal of physiology and pharmacology. 2009;87(9):729-35.
Spencer JP. Food for thought: the role of dietary flavonoids in enhancing human memory, learning and neuro-cognitive performance: Symposium on ‘Diet and mental health’. Proceedings of the Nutrition Society. 2008;67(2):238-52.
Houshmand G, Tarahomi S, Arzi A, Goudarzi M, Bahadoram M, Rashidi-Nooshabadi M. Red Lentil Extract: Neuroprotective Effects on Perphenazine Induced Catatonia in Rats. Journal of clinical and diagnostic research: JCDR. 2016;10(6):FF05.
Kulkarni S, Arzi A, Kaul P. Modification of drug-induced catatonia and tremors by quipazine in rats and mice. The Japanese Journal of Pharmacology. 1980;30(2):129-35.
Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut P-O, Feyder M, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in neurobiology. 2015;132:96-168.
Mercer LD, Kelly BL, Horne MK, Beart PM. Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis: investigations in primary rat mesencephalic cultures. Biochemical pharmacology. 2005;69(2):339-45.
Vauzour D, Vafeiadou K, Rodriguez-Mateos A, Rendeiro C, Spencer JP. The neuroprotective potential of flavonoids: a multiplicity of effects. Genes & nutrition. 2008;3(3):115.
Ballard CR, Junior MRM. Health Benefits of Flavonoids. Bioactive Compounds: Elsevier; 2019. p. 185-201.
Amarowicz R, Estrella I, Hernández T, Dueñas M, Troszyńska A, Kosińska A, et al. Antioxidant activity of a red lentil extract and its fractions. International Journal of Molecular Sciences. 2009;10(12):5513-27.
Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. American Journal of Psychiatry. 1998;155(9):1207-13.
Bishnoi M, Chopra K, Kulkarni SK. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacology Biochemistry and Behavior. 2008;88(4):511-22.
Naidu P, Kulkarni S. Quercetin, a bioflavonoid, reverses haloperidol-induced catalepsy. Methods and findings in experimental and clinical pharmacology. 2004;26(5):323-6.
Dietrich-Muszalska A, Olas B, Kontek B, Rabe-Jabłońska J. Beta-glucan from Saccharomyces cerevisiae reduces plasma lipid peroxidation induced by haloperidol. International journal of biological macromolecules. 2011;49(1):113-6.
Taira T, Saito Y, Niki T, Iguchi‐Ariga SM, Takahashi K, Ariga H. DJ‐1 has a role in antioxidative stress to prevent cell death. EMBO reports. 2004;5(2):213-8.
Rosen KM, Veereshwarayya V, Moussa CE, Fu Q, Goldberg MS, Schlossmacher MG, et al. Parkin protects against mitochondrial toxins and β-amyloid accumulation in skeletal muscle cells. Journal of Biological Chemistry. 2006;281(18):12809-16.
Angeline MS, Sarkar A, Anand K, Ambasta R, Kumar P. Sesamol and naringenin reverse the effect of rotenone-induced PD rat model. Neuroscience. 2013;254:379-94.
Zhang ZJ, Cheang LCV, Wang MW, Lee SM-Y. Quercetin exerts a neuroprotective effect through inhibition of the iNOS/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish. International journal of molecular medicine. 2011;27(2):195-203.
Angelopoulou E, Pyrgelis ES, Piperi C. Neuroprotective potential of chrysin in Parkinson's disease: Molecular mechanisms and clinical implications. Neurochemistry international. 2020;132:104612.
Madani E, EL-Shenawy S, Arbid M, Abd E, Attia A. Neuropharmacological effects of naringenin, harminee and adenosine on parkinsonism induced in rats. Der Pharmacia Lettre. 2016;8(5):45-57.
Magalingam KB, Radhakrishnan A, Haleagrahara N. Protective effects of quercetin glycosides, rutin, and isoquercetrin against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in rat pheochromocytoma (PC-12) cells. International journal of immunopathology and pharmacology. 2016;29(1):30-9.
Motawi TK, Darwish HA, Hamed MA, El-Rigal NS, Naser AFA. A therapeutic insight of niacin and coenzyme Q10 against diabetic encephalopathy in rats. Molecular neurobiology. 2017;54(3):1601-11.
Khodayar MJ, Salehi S, Rezaei M, Siahpoosh A, Khazaei A, Houshmand G. Evaluation of the effect of naringenin on pentylenetetrazole and maximal electroshock-induced convulsions in mice. Jundishapur J Nat Pharm Prod. 2017;12:e31384.
Jäger AK, Gauguin B, Adsersen A, Gudiksen L. Screening of plants used in Danish folk medicine to treat epilepsy and convulsions. Journal of ethnopharmacology. 2006;105(1-2):294-300.
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation. Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This work is licensed under a Creative Commons license (CC-BY). However, the license permits any user to read, copy, redistribute and and make derivative the material in any medium or format for any purpose, even commercially.
